Teva, IRS Resolve $44M Case Over Patent Defense Costs
By Molly Moses · May 26, 2026, 6:16 PM EDT
Teva Pharmaceuticals and the IRS resolved a $44.3 million dispute Tuesday that stemmed mostly from disallowed patent defense costs, agreeing that Teva had a $15.9 million overpayment for 2009 and had...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login
